Clinical Trial Update: A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating SCB-219M for chemotherapy-induced thrombocytopenia is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Thrombocytopenia

Drugs mentioned

• SCB-219M

Snippet

Sponsor: Sichuan Clover Biopharmaceuticals, Inc. | Conditions: Chemotherapy-induced Thrombocytopenia (CIT) | Phase 1 | Status: ACTIVE_NOT_RECRUITING